Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 versus individualized medical management in heart failure with preserved ejection fraction
2016-003410-28Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Novartis. Primary endpoint: Change from baseline in N-terminal pro-brain natriuretic peptide (NT-proBNP) after 12 weeks. Started Mar 2017; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2016-003410-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003410-28.